How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
How a strong corporate board can help ignite success in these regions.
Anthony Arnold offers an overview and update of bioelectronic medicine.
Poland's government is aiming to make the Eastern European country a biotech powerhouse.
Exits from the CMO industry are a more recent development that seems to be picking up momentum.
Unprecedented policy and access issues threaten R&D momentum.
The need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.
Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
Gayle Johnston explains what makes CuraScript SD uniquely able to serve its broad range of customers.
The Expert Determination standard of protecting patient privacy can answer the growing demand for better data for research and analytics in healthcare.
Many big pharma companies have been wary of social media. But if you truly want to be customer centric you do need to be in dialogue with your customers - and social media can allow that, writes Will Simpson.
As the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.
The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
Ruth Trzcienski's reviews FDA's new Procedural Guidance to help manufacturers ensure consistency with the FDA-required labelling.
A new approach to reviving industry collaborations.
The key steps to easing rising complexity and cost factors.
The key steps to easing rising complexity and cost factors.
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Brooke Ringel and Eric McClafferty outline steps companies should take to ensure compliance with export controls.
Geoff Newman looks at how pharma and biotech interim management has evolved in the last 20 years.
Laurent Fanichet outlines four ways pharma companies can use cognitive search and search-based applications to improve competitiveness.
How integrating next-generation sequencing data can advance efforts in immuno-oncology research.
An FDA Memo addressing First Amendment legal issues regarding off-label use of medical products falls short of the necessary clarity, write Jamie Kendall and Alexandra Schulz.